Ranking Profile - Enanta Pharmaceuticals Inc

Introduction

Enanta Pharmaceuticals Inc (Enanta) is a biotechnology company. It discovers and develops small-molecule drugs for the treatment of viral infections and liver diseases. The company’s lead product candidate includes EDP-305, a farnesoid X receptor (FXR) agonist intended for the treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Enanta also develops EDP-938, a potent N-protein inhibitor for the respiratory syncytial virus; and programs to discover and develop chemical entities for the treatment of the hepatitis B virus. The company also develops and markets protease inhibitor compounds for the treatment of the hepatitis C virus through collaborative development and license agreement with AbbVie. Enanta is headquartered in Watertown, Massachusetts, the US